Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 12/20 | 0.38 |
| ▸ | GSK3A | P49840 | 6/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | CTSG | P08311 | 1/20 | 0.38 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5491108 | 1.00 | ADORA1 (0.38) | ADORA1ADORA3ADORA2AGSK3BGSK3A | |
| SCHEMBL8318141 | 0.88 | ADORA1 (0.40) | ADORA1ADORA3ADORA2APSMB5 | |
| SCHEMBL5491537 | 0.88 | ADORA1 (0.40) | ADORA1ADORA3ADORA2APSMB5 | |
| SCHEMBL8320279 | 0.87 | MAPK1 (0.37) | ADORA1GSK3BCDK1CDK2CDK5 | |
| SCHEMBL5488429 | 0.87 | MAPK1 (0.37) | ADORA1GSK3BCDK1CDK2CDK5 | |
| SCHEMBL5489292 | 0.83 | MMP1 (0.35) | ADORA1ADORA3ADORA2A | |
| SCHEMBL2958400 | 0.83 | MMP1 (0.35) | ADORA1ADORA3ADORA2A | |
| SCHEMBL8312713 | 0.83 | MMP1 (0.35) | ADORA1ADORA3ADORA2A | |
| SCHEMBL8320239 | 0.82 | PSEN1 (0.42) | — | |
| SCHEMBL8317922 | 0.82 | L3MBTL1 (0.41) | ADORA3ADORA2ACDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2511267-A1 | 3-((N-ACYLATED AMINOACYL)AMINO)PYRAZOLES AS INHIBITORS OF BETA-AMYLOID PEPTIDE PRODUCTION USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals Inc. (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-1633350-B1 | ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS | ELAN PHARM INC (US) | 2012-10-03 | — | — | EP | disclosed |
| US-20100280066-A1 | ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS | TUNG JAY S | 2010-11-04 | — | — | US | disclosed |
| US-20100280066-A1 | ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS | TUNG JAY S | 2010-11-04 | — | — | US | disclosed |
| US-7759382-B2 | such as N-{5-[1-(4-chloro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-propionamide, used for inhibiting beta-amyloid peptide release and/or biosynthesis, inhibiting gamma-secretase activity, prevention and treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759382-B2 | such as N-{5-[1-(4-chloro-phenyl)-1-methyl-ethyl]-2H-pyrazol-3-yl}-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-propionamide, used for inhibiting beta-amyloid peptide release and/or biosynthesis, inhibiting gamma-secretase activity, prevention and treatment of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-20070197624-A1 | Acylated amino acid amidyl pyrazoles and related compounds | ELAN PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070197624-A1 | Acylated amino acid amidyl pyrazoles and related compounds | ELAN PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2005009344-A2 | ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280066-A1 | ACYLATED AMINO ACID AMIDYL PYRAZOLES AND RELATED COMPOUNDS | APP, BACE1, APH1A | ADORA1 732/4885ADORA3 959/4885ADORA2A 3254/4885 |
| US-20070197624-A1 | Acylated amino acid amidyl pyrazoles and related compounds | APP, BACE1, APH1A | ADORA1 732/4885ADORA3 959/4885ADORA2A 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.